17 April 2019

Hivpoint Helsinki welcomes Pre-Exposure Prophylaxis – Finnish national guidelines are here, and generic medicines hit the market soon

The National Institute for Health and Welfare recommends PrEP for people with a high risk for HIV transmission. As a part of a comprehensive prevention program, PrEP has reduced new HIV transmissions in all countries where it is available. When used correctly, PrEP provides up to 99% reduction in HIV risk. The Finnish national guidelines are released today, 17 April 2019.
17 April 2019

Letter to FDA Regarding Application for Descovy as Pre-Exposure Prophylaxis for HIV

TAG and PrEP4All sent this letter to Dr. Debra Birnkrant of the FDA, outlining and expressing our serious concerns about Gilead’s supplemental New Drug Application for Descovy (FTC/TAF) as HIV-1 preexposure prophylaxis (PrEP). There are several specific recommendations in the letter for this approval process, including recomending that the FDA convene a public meeting of the Antiviral Drug Advisory Committee.
17 April 2019

Pre-Exposure Prophylaxis for HIV officially launched in Hanoi

Pre-Exposure Prophylaxis (PrEP) service for HIV prevention was officially launched in Hanoi on April 16.
15 April 2019

London councils agree to take 60% new PrEP trial patients, but it might not be enough

A stalemate over who would take more patients on to PrEP trial has ended. London councils have agreed to increase places on city PrEP trial.
15 April 2019

PrEP should be offered urgently to gay men with a recent STI or multiple condomless partners

Analysis of men who acquired HIV in the deferred arm of the PROUD study highlights two risk factors that are far more important than any others. “A recent history of syphilis or rectal chlamydia/gonorrhoea, or multiple ncRAI [receptive anal intercourse without a condom] partners indicates a high imminent risk of HIV infection,” Ellen White
12 April 2019

More Londoners to receive HIV prevention medicine

In a boost to HIV prevention in the capital, London boroughs have agreed to provide over 4,000 extra places on the PrEP Impact Trial. The trial – a national programme led by NHS England in partnership with Public Health England and local authorities – supplies PrEP (an HIV prevention medicine) free of charge to individuals considered to be at high risk of exposure to HIV. The expansion, which will take place over the coming weeks, represents a 60% increase in the trial places available to Londoners. London already accounts for 7,609 trial places – a higher figure than the rest of England combined.
11 April 2019

London: Tower Hamlets Mayor calls for Government to fund PrEP for all to stop HIV transmission

John Biggs, Mayor of Tower Hamlets has written to Matt Hancock the Secretary of State for health, to call for the funding of HIV treatment that could stop the spread of HIV, saving the NHS millions of pounds.
10 April 2019

PrEP: Camden councillor Jonathan Simpson urges NHS to extend availability of preventative HIV drug

A Camden councillor urged the government to make the preventative HIV drug PrEP more available, during a passionate speech at a council meeting last night.
9 April 2019

Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find

For years, the U.S. HIV prevention community has known that pre-exposure prophylaxis (PrEP) is prohibitively expensive for many patients who need it. Now, new research presented at the 2019 National HIV Prevention Conference (NHPC) in Atlanta finds that not only is PrEP expensive for individual patients, it's also not cost-effective for the health system as a whole.
9 April 2019

Racism, marginalisation and PrEP stereotypes affect PrEP uptake for black MSM in London

Black men who have sex with men (MSM) in London experience a unique set of motivations and barriers to using pre-exposure prophylaxis (PrEP), according to the results of a recent qualitative study published in Sexually Transmitted Infections. This research was carried out by T. Charles Witzel and colleagues at the London School of Hygiene and
8 April 2019

Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis

Filing Supported by Data Demonstrating Non-inferiority Compared to Truvada® Coupled with Bone and Renal Safety Advantages in People at Risk of Sexually Acquired HIV Infection
7 April 2019

English clinic survey finds that 40% of gay men with new hepatitis C infections are HIV negative

A study of gay and bisexual men diagnosed with recently acquired hepatitis C infection and treated in three English clinics has found that 40% of them were HIV negative, the 25th Annual Conference of the British HIV Association (BHIVA) was told in Bournemouth this week, though all the HIV-negative men were in London.Daniel Bradshaw of
5 April 2019

The CDC Director got shouted down by angry AIDS activists during a completely tone deaf speech

Dr. Robert Redfield, director of the Centers for Disease Control, was shouted down by activists during a speech to the AIDSWatch conference after he refused to explain why the government agency wasn’t enforcing its patent on the HIV drug Truvada.
5 April 2019

Raltegravir plus lamivudine is likely to work as PrEP

A combination of the drugs raltegravir and lamivudine produced acceptable drug levels in both women and men, in rectal and vaginal tissues, suggesting that the two drugs could provide an effective alternative to tenofovir-based pre-exposure prophylaxis (PrEP), the 25th Annual Conference of the British HIV Association (BHIVA) heard in Bournemouth yesterday.Dr
2 April 2019

First year of PrEP in Scotland: more users than expected, few dropouts, few HIV infections

The recent report on the first year of the implementation of  pre-exposure prophylaxis (PrEP) through the National Health Service (NHS) in Scotland concludes: “Year one has been a resounding success in terms of establishing a new nationwide service – the first of its type in the UK and one of the first worldwide.” In
19 March 2019

Urine test can provide accurate point-of-care results about PrEP adherence

A point-of-care urine test can accurately determine if a person is adherent to tenofovir-based pre-exposure prophylaxis (PrEP), according to research presented to the recent Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle. The test checks for antibodies to tenofovir and was tested in a trial of 30 people in Thailand who
13 March 2019

TAF: Quick-dissolve combination PrEP insert is effective against HIV infections in monkeys; intermittent solo pill less so

Two studies in monkeys of experimental pre-exposure prophylaxis (PrEP) regimens featuring the drug tenofovir alafenamide (TAF) produced differing results when presented at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle. As a third study suggested, the results may partly be due to the way TAF is absorbed into cells. TAF
10 March 2019

People stay on PrEP for 14 months on average in the US, study finds

Whether HIV pre-exposure prophylaxis (PrEP) is effective depends on whether people take it appropriately, at the times when they are at risk of HIV. But we know surprisingly little about how people receiving PrEP through health services take PrEP, in terms of whether they take it correctly, how long they take it for, and
7 March 2019

How many people who have used PrEP get HIV the same year? New York study finds out

One question often asked about pre-exposure prophylaxis (PrEP) use is how frequently people start PrEP while unknowingly having HIV, often because they have acquired it so recently that they are still in the ‘window period’ when it cannot be detected. If someone has undiagnosed HIV and takes PrEP, this can cause HIV drug
6 March 2019

Descovy is non-inferior to Truvada for daily PrEP

A daily pill containing the newer formulation of tenofovir in combination with emtricitabine (Descovy) had a comparable protective effect to the existing daily pill which contains the older tenofovir and emtricitabine (Truvada), Dr Brad Hare of the Kaiser Permanente San Francisco Medical Center told the Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle